Dispatches from BIO 2016

Brammer Bio opens new cell and gene therapy manufacturing facility

By Melissa Fassbender

- Last updated on GMT

Brammer Bio's CEO Mark Bamforth at BIO International.
Brammer Bio's CEO Mark Bamforth at BIO International.

Related tags Gene

The new 50,000 square foot facility in Lexington, MA will be dedicated to late phase development and commercial manufacturing for advanced cell and gene therapies.

The contract development and manufacturing organization (CDMO) announced the establishment of the new facility at BIO International, in San Francisco this week.

The new facility will include space for Phase III and commercial production of viral vector-based and cell-based advanced therapies and is expected to be qualified and operational by the second quarter of 2017.

As Outsourcing-Pharma.com previously reported​, the company recently merged with Flordia Biologix – adding capabilities in process development and phase I/II manufacturing.

We are now entering the year of personalized medicine​,” Brammer Bio President and CEO Mark Bamforth said at a press event at BIO International on Tuesday. “What has been an idea and a plan in people’s minds for several decades is now coming to fruition​.”

Bamfroth added that the company will eventually employ up to 200 people in the new facility with a total of $50m invested, “to provide these therapies for our clients to they can bring them to patients around the world​.”

Massachusetts’s Secretary of Economic Development, Jay Ash, also spoke at the event, thanking Brammer for its commitment to the state.

A couple of years ago when Massachusetts was talking about being number one in life sciences, that meant research and development … but we’re now having conversation after conversation about manufacturing​,” he said. 

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers